Sign In
Last checked at 
25 Mar 2013 14:42
Hikma Pharmaceuticals PLC - Vesting of 2010 LTIP
LONDON, 25 March 2013: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received conditional share awards which vested on 23 March 2013 under the 2005 Long Term Incentive Plan ("LTIP") and were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.
Bassam Kanaan
| Vesting of LTIP 2010 | 49,476 (0.02% ISC) | 25 March 2013 | £10.24 | Nil | 468,134 (0.24% ISC) | ||
Michael Raya
| Vesting of LTIP 2010 | 44,384 (0.02% ISC) | 25 March 2013 | £10.24 | Nil | 56,584 (0.03% ISC) | ||
Riad Mishlawi | Vesting of LTIP 2010 | 17,660 (0.01% ISC)
| 25 March 2013 | £10.24 | Nil | 60,260 (0.03% ISC) | ||
Khalid Nabilsi | Vesting of LTIP 2010 | 23,063 (0.01% ISC)
| 25 March 2013 | £10.24 | Nil | 219,847 (0.11% ISC) | ||
| ||||||||
- ENDS -
Enquiries
Peter Speirs +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.
Follow the stocks
